GeneDx (WGS) announced that the FDA has granted breakthrough device designation for its whole genome and exome tests associated with causes of life-threatening diseases or genetic disorders to aid in diagnosis of symptomatic patients.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx initiated with a Buy at Canaccord
- WGS, PONY, QSI, SLMT: Cathie Wood Snaps Up Biotech and AI Stocks, Trims Stake in a Semiconductor Name
- GeneDx announces Mimi Lee as chief precision medicine officer
- GeneDx selected by Florida State University as partner for Sunshine Genetics Act
- DASH, DE, BABA: Cathie Wood Loads Up on DoorDash, Deere & Alibaba, Trims Stakes in ADPT and Others